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HOW MISSING A TREATMENT OF MIXED AMPHETAMINE SALTS EXTENDED 
RELEASE AFFECTS PERFORMANCE IN TEEN DRIVERS WITH ADHD 
 
Lana M. Trick & Ryan Toxopeus 
Department of Psychology, University of Guelph 
Guelph, Ontario, Canada 
Email: ltrick@uoguelph.ca 
 
Summary: Mixed Amphetamine Salts Extended Release (MAS-XR or Adderall 
XR®) is a stimulant medication used to control symptoms of ADHD. People 
occasionally fail to take their medications. The goal of this pilot study was to 
assess the impact of a single missed medication on driving performance in 14 teen 
drivers with ADHD mixed type as a function of driving skill. A double-blind 
placebo control crossover design was used and participants were tested in a 
driving simulator. On the evening of the first day, baseline measures of driving 
performance were taken to assess driving skills (on medication). Then on two 
consecutive days drivers were tested three times a day, one day on medication and 
the other day off. Results indicated increased collisions and hazard response time 
off medication, with performance worst on 36 hours post-medication. Participants 
with the least developed driving skills benefited most from medication. This 
highlights the importance of consistent medication use in inexperienced teen 
drivers with ADHD. 
 
OBJECTIVES  
 
Drivers with Attention-Deficit-Hyperactivity-Disorder (ADHD) are at higher risk for adverse 
driving outcomes (e.g., Barkley 2007). These dangers are especially notable for teens with 
ADHD given teens are generally at higher risk (e.g. Transport Canada, 2011). Studies suggest 
some ADHD medications may improve driving performance (e.g. Barkley & Cox, 2007; 
Biederman et al. 2012; Cox et al. 2012) but it is not at all uncommon for teens with ADHD to 
skip medications. One goal of this pilot study is to investigate how driving performance changes 
over the course of a day as a function of a single missed dose of Mixed Amphetamine Salts 
Extended Release capsules (MAS-XR known as Adderall XR®: a 3:1 mixture of d- to l- 
amphetamine salts with respective peak plasma concentration times of 7 and 8 hours; post-
administration elimination half lives of 9 and 11 hours in adults and 11 and 13 hours for 
adolescents < 75 kg, Shire 2012). There is less research on the effect of MAS-XR on driving 
than there is on the other stimulant medications and results are mixed (e.g. Cox et al. 2008; Kay, 
Michaels, & Pakull, 2009; Thorndike et al. 2005). Nonetheless, it is important to note that at this 
point, there has never been a study focusing on individuals for whom MAS-XR is the treatment 
of choice. A double blind placebo control crossover design was used in driving simulator testing.  
 
As driving skills develop certain aspects of driving performance become automatic, which is to 
say that they do not require as much attention.  The second goal of the study was to determine 
whether the effects of withdrawing medication vary depending on the level of driving skill in 
teen drivers with ADHD. There are a number of different driving skills and in particular, it is 
possible that braking and steering performance may be governed by different attentional 
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mechanisms (Wickens, 2002). Thus, as an initial strategy, three different aspects of poor driving 
skill were assessed in the baseline drive (on medication), to be later used as covariates in analysis 
of covariance. Two indices of braking skill were derived. One was designed to measure 
inattention and delayed response (the delayed hazard response index). The other was designed to 
measure variability in braking, which includes unnecessary braking, hitting the gas too quickly 
before coming to a full stop at stop signs (rolling stops), and SD of hazard RT, all of which may 
reflect problems in impulse control (the erratic braking index). The delayed hazard response 
index was created by calculating each driver’s z score for collisions and median hazard RT in the 
baseline drive. These z scores were averaged to create the delayed hazard response composite, 
with low scores indicating rapid hazard response compared to the other drivers in the sample. 
The erratic braking index was created by taking z scores for the SD of hazard RT, the number of 
rolling stops, and the number of unnecessary braking events in the baseline drive, and then 
averaging the z scores to obtain an index of erratic braking, with high scores indicating erratic 
response compared to the other drivers in the sample. A third measure, the erratic steering index, 
was calculated based on averaged z scores for the SD of lane position in different speed zones 
and in straight and winding areas. The three indices seem to represent different aspects of driving 
skill, insofar as correlations between indices were weak and non-significant: r (12) =  -0.15, 
+0.06, and +0.27, p > .2 for delayed hazard response and erratic braking, delayed hazard 
response and steering, and erratic braking and steering respectively. 
 
There were two predictions. The first was that driving performance would be worse on the no 
medication day, and in particular, at the final test on that day. The second was that the difference 
between medicated an un-medicated driving performance would be largest for those with the 
least developed driving skills as measured in the baseline drive (on medication).  
 
METHODS 
 
Participants  
 
Participants were 14 healthy drivers with ADHD combined type (M age = 17 years: 2 months; 2 
females). They were selected because MAS-XR was treatment of choice (other medications were 
less effective). All had used MAS-XR for 2 or more years: Males M weight = 73 kg; M dosage = 
55 grams (SD = 8.2); Females M weight = 63 kg; M dosage = 45 grams (SD = 7.1). Participants 
with social anxiety were excluded because procedure required driving with a research assistant. 
Other diagnosed co-morbidities were allowed: 6 had co-morbid Anxiety, 8 had Learning 
Disabilities, and all 14 had Oppositional Behaviour. MAS-XR dosage was manipulated but other 
medications were maintained: 1 used Respiridol, 1 used Wellbutrin, 2 used Atomoxetine. (When 
the study began there was no research on these drugs and driving. The inclusion of participants 
using this Atomoxetine means the study may underestimate the influence of MAS-XR.) All 
drivers had been licensed less than 3 years but none had a full Ontario (G) license. Eleven had a 
G1, which requires driving under supervision and can be obtained at the age of 16 with a written 
test. The remaining 3 had a G2, which can be obtained 1 year after the G1 with a road test.  
Design 
 
This study used a double-blind placebo control design, where individuals experienced both 
medication and placebo conditions but on different days. There were two within-subjects 
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independent variables: Condition (Medication, No medication), and time of test (1, 8, and 12 
hours post-administration). Three indices of driving skill were measured on the evening of the 
first day, before the manipulation began: delayed hazard response, erratic braking, and erratic 
steering.  These baseline measures were used as covariates in later analyses. Then on the second 
and third days participants were tested three times a day, one day on medication and one day off 
medication.  Seven participants were randomly assigned to do the medication day first and the no 
medication day second. The remaining seven did the conditions in the opposite order. (For each 
order of presentation there were six males and one female.) 
 
Apparatus and Stimuli  
 
Testing was performed in a DriveSafety DS-600c high fidelity fixed base driving simulator. This 
simulator includes a full car body surrounded by viewing screens that afford a 300o wrap around 
virtual field of view (five-50o screens in front, and one behind). Seven unique 25-minute drives 
through the country and small towns were created: a baseline drive and six experimental drives. 
All involved straight and winding sections and oncoming and trailing traffic. Speed limit 
postings ranging between 50-80 kph appeared on the side of the road every 200 meters. Hazards 
emerged periodically from the periphery (cyclists, pedestrians, vehicles, and animals) and drivers 
had to brake to avoid them (hazards appeared 3.5 seconds before collision point on the road). 
 
Procedure  
 
Simulator testing occurred on three consecutive days. In each case a research assistant was 
present in the vehicle with the driver to administer instructions and ensure they were followed. 
This control was necessary given that it is important to distinguish deficits in driving per se from 
deficits in the comprehension and adherence to instructions for the experimental protocol. On the 
evening of the first day, participants were given a 10-minute training drive to familiarize 
themselves with the simulator and then they did their first 25-minute drive (8-10 hours post-
medication), the baseline drive, that was used to create indices of driving skill. The second day 
of testing began with administration of the treatments at 7:30 – 8 a.m.  At that time participants 
ate breakfast. They were also required to consume 2 tbsp of raspberry jam that had been prepared 
by the study coordinator. The jam was either pure raspberry jam or jam with the participant’s 
normal dosage of MAS-XR sprinkled in so that it was undetectable. Mixing MAS-XR with food 
in this way does not compromise bioavailability or the drug’s effect (Shire, 2012). Participants 
were tested in the simulator 1, 8, and 12 hours after administration of the jam (with a different 
25-minute drive for each test). The third day was similar to the second, but the participants that 
received medication on the first day received no medication on the second, and vice versa. 
Personnel involved in testing the drivers were kept blind to the manipulation. 
 
RESULTS 
 
No data were lost due to simulator sickness. Three indices of driving skill were derived from the 
baseline drive to include as co-variates: delayed hazard response, erratic braking, and erratic 
steering. Factorial analyses of covariance were then performed, using these covariates and partial 
η2 was used as an index of effect size. There were two within subjects factors: Condition 
(Medication, No medication) and Test (1, 8, and 12 hours post-administration of the jam). The 
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Geisser-Greenhouse correction was applied to modify the degrees of freedom as needed in the 
event of violation of the sphericity assumption. Tukey’s HSD was used for post-hoc tests of 
means. The following strategy was used in data analysis. Because of the limited sample size, care 
was taken to minimize the number of factors/covariates and thus maximize degrees of freedom. 
In each analysis, only one index of driving skill was entered at a time as a covariate, beginning 
with the covariate most closely related to the dependent measure in question. If the covariate 
interacted with condition, and moreover, the effects remained significant when order of 
presentation (medication day first, no medication day first) was also entered in as a covariate, 
groups were created based on the index, comparing the best and worst seven drivers to clarify the 
nature of the interaction. (In each case, approximately half of each group of seven drivers 
experienced the medication condition first.)  
 
Although many measures of driving performance were collected, the focus will be on collisions 
and median hazard RT in this paper. There will be no further discussion of the erratic steering 
index, as it did not enter into any effects (F < 1 for all). There will also be no further discussion 
of driving speed because it was unrelated to medication condition (p > .1) and drivers generally 
adhered to posted limits (e.g. M speeds = 52.7 and 82.8 kph in the 50 and 80 kph zones). 
  
The medication condition had an effect on the number of collisions, but the effect was most 
pronounced at the end of the day (Figure 1). Analyses of covariance were performed with 
baseline delayed hazard response index as a covariate. This analysis revealed a significant 
Condition X Test interaction (F(1.94,23.32) = 3.60, p = .045, partial η2 = .23). Tests of means 
revealed that on the Medication day there was a significant drop in the number of collisions over 
successive tests (M reduction = 0.5 collisions per drive from the first to the third drive, p = .03) 
whereas on the No medication day the number of collisions increased over the course of the day 
(M increase = 0.14 collisions per drive, p > .1). Overall, the difference between the medication 
and no medication condition only approached significance on the third and last testing of the day 
(M difference = 0.5 collisions/drive, p = .054). 
 
Figure 1. Adjusted mean number of collisions per drive co-varying out the effects  
of the delayed braking index. SE bars included 
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There were individual differences in the response to medication. Surprisingly, it was erratic 
braking index that proved to be the more interesting covariate insofar as it interacted with the 
manipulations. There was a significant Erratic braking X Condition interaction (F(1,12) = 9.41, p 
= .01, partial η2 = .44), and an Erratic braking X Test interaction (F(1.29,15.5) = 9.58, p = .005, 
partial η2 = .44). These effects remained significant when order of presentation was included as 
a covariate (p < .005 for all after order was included as a covariate; order did not enter into any 
effects or interactions so it will not be included in the following analyses). To clarify the nature 
of these interactions, the participants were divided into two groups in terms of their erratic 
braking scores (less erratic, more erratic). A Braking group X Condition interaction emerged 
(F(1,12) = 5.15, p = .042, partial η2 = .30). The group that had the most erratic braking in the 
baseline drive benefited most from the treatment. For the seven drivers who were most erratic in 
their braking, medication reduced the number of collisions per drive by M = 0.48 (p = .12) 
whereas for the ones who were least erratic in their braking, the medication produced a slight 
increase in the collisions per drive (with 0.29 more collisions per drive with medication, p > .2).  
 
Medication condition had an effect on hazard RT, but once again, effects were strongest at the 
end of the day (see Figure 2). Analyses of covariance revealed that the delayed hazard response 
index was a significant covariate in analyses of median hazard RT (F(1,12) = 6.08, p = .03, 
partial η2 = .34). Test had a significant effect (F(1.88, 22.58) = 3.93, p = .037) and there was 
also a marginal Condition X Test interaction (F(1.89, 22.74) = 3.16, p = .064, partial η2 = .21). 
Tests of means revealed a significant reduction in median hazard RT over the course of the day 
in the medication condition (M reduction from time 1 to time 2 = 66 ms, p = .051; M reduction 
from Time 1 to time 3  = 92 ms, p = .004) whereas there was only a 13 ms reduction in hazard 
response time over the course of the day in the no medication condition (p > .2). The difference 
between the medication and no medication conditions only became significant on the final 
testing of the day (reduction in median RT = 54 ms, p = .029).  
 
Figure 2. Adjusted median hazard RT co-varying out the effects of the delayed 
 braking index. SE bars included 
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group experienced the Medication condition first). To clarify the nature of the effect, participants 
were divided into two groups based on their delayed hazard response index, and there was an 
effect of Test (F(1.93, 23.12) = 4.19, p = .029, partial η2 = .26), a Condition X Test interaction 
(F(1.87, 22.45) = 3.86, p = .039, partial η2= .24) and Condition X Test X Hazard skill group 
interaction (F(1.87, 22.45) = 3.58, p = .047, partial η2 = .23). Overall this analysis revealed that 
the medication produced the largest reduction in hazard RT in the group that had the most 
delayed hazard response on the baseline drive. For the drivers with the most delayed hazard 
response, medication produced a 137 ms reduction in median hazard RT from the first to the 
third testing (p = .025 for time 1 and time 2, and p = .007 for Time 1 and Time 3) whereas on the 
No Medication day, there was only a 17 ms reduction in median hazard RT from the first to third 
testing (p > .1) for the drivers with delayed hazard response. Hazard RTs in for drivers with the 
group with the least delayed hazard response were marginally lower on the Medication than No 
Medication day at the second testing (M difference = 97 ms, p = .059, and at the third testing M 
difference = 76 ms, p = .089). For the more skilled drivers, medication produced a 48 ms 
reduction in median hazard RT (p = .16 though) whereas the improvement from test 1 to test 3 
was only 8 ms in the No Medication condition, and the differences between the Medication and 
No Medication hazard RT never approached statistical significance (p > .2). Scores on the erratic 
braking index were not significant predictors of median hazard RT (p > .1).  
 
CONCLUSIONS 
 
When teen drivers missed a single treatment of MAS-XR their driving performance deteriorated 
on the following day. Effects were strongest 36 after their last treatment of MAS-XR (the last 
testing of the day). Median hazard RT was slightly higher off medication (M difference = 54 ms 
at the last test of the day) but more important, when drivers were off medication there were more 
collisions: M difference = 0.5 collision at the final test of the day. This finding that is especially 
alarming given that each test drive was only 25 minutes long. The amount of deterioration off-
medication varied as a function of driver skill as measured on the baseline drive. Drivers with an 
erratic braking style (unnecessary stops, high SD of hazard RT, rolling stops at stop signs, etc.) 
displayed a bigger increase in the number of collisions off medication. Similarly, drivers with 
delayed hazard response in the baseline drive displayed a significantly larger increase in median 
RT on days where they were off medication. Thus, it appears that there is deterioration in 
performance given the time off medication, but the amount of deterioration varied based on the 
skills of the driver. This finding highlights the importance of consistent medication use when 
teen drivers with ADHD are first learning to drive. 
 
This study is limited by small sample size and the heterogeneity of the participants, who were 
chosen based on their age and response to MAS-XR. Some had co-morbid disorders and were 
using other medications (maintained throughout the study), complicating interpretation of results. 
Most important, it seems probable that that the participants were not driving the way that they 
might normally choose. The need to control the conditions during the drive also forced drivers to 
be on their best behaviour. For example, a number of the participants complained that they 
wanted to have music on in the car. As well, the research assistant in the vehicle had to resist 
many conversational gambits (she was directed to avoid entering into conversation during the 
drive and participants knew this). The presence of the research assistant, the frequent reminders 
of the speed limit (every 200 m), the absence of in-vehicle distractions (conversation, the radio, 
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cellular phones and portable computing devices), and the relatively novelty of the situation may 
have served to make the teen drivers drive more conservatively.  
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